Charlie Hao
Chief Scientific Officer Degron Therapeutics
Chunhai (Charlie) Hao is Bicentennial Chair and Professor at Indiana University School of Medicine and Co-Founder of HB Therapeutics and Degrome Therapeutics. A physician-scientist with more than 30 years of experience, he has pioneered molecular glue approaches targeting oncogenic proteins, neurodegenerative diseases, and aging-associated pathways through disease biology-driven, structure-guided, and AI-enabled drug discovery.
Seminars
Thursday 28th January 2027
Panel Discussion: Deploying Molecular Glues to Tackle Neurodegeneration’s Toughest Targets
2:30 pm
- How can molecular glues be leveraged to target pathogenic protein aggregates and drive the selective clearance of disease-causing proteins across Alzheimer’s, Parkinson’s, and Huntington’s disease?
- What strategies are proving most effective for engineering brain-penetrant molecular glues that improve CNS exposure and target engagement while enhancing the translational potential of neurodegeneration programs?
- How can target engagement be most effectively validated in disease-relevant neuronal models to better understand therapeutic impact and de-risk progression into clinical development?
